Apellis Pharmaceuticals (NASDAQ: APLS) reported quarterly earnings of $1.67 per share which beat the analyst consensus estimate of $0.92 by 80.93 percent. This is a 463.04 percent increase over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $458.578 million which beat the analyst consensus estimate of $406.678 million by 12.76 percent. This is a 132.98 percent increase over sales of $196.830 million the same period last year.